AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01497197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GONAL-f®
Description: GONAL f® 300 international units \[IU\] per day as subcutaneous injection using liquid pen.
Study NCT01497197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luveris®
Description: Luveris® 150 IU per day lyophilized powder for subcutaneous injection.
Study NCT01497197 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human chorionic gonadotropin (r-hCG)
Description: A single injection of r-hCG (Ovidrel®/Ovitrelle®) 250 mcg to induce final oocyte maturation.
Study NCT00873925 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous UCB
Description: Umbilical Cord Blood stem cells CAN be collected and frozen immediately after birth in private and public cord blood banks. If a child with recent onset T1D has their OWN cord blood in storage they may qualify for this study. The cells would be released to the University of Florida where we would perform a single IV infusion of the cells once they have been thawed and washed. Depending on how the cells are stored, it may be possible to keep some portion of the cells in storage for future use.
Study NCT00873925 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3 FA
Description: Omega 3 Fatty Acids commonly found in fish oil may play an important role in preserving beta cell function via their anti-inflammatory actions. Those subjects randomized to treatment will take a daily supplement supplied as a capsule that can either be swallowed whole or opened so the contents can be mixed with food.
Study NCT00873925 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D is important for calcium absorption and bone health but may also play an important role in promoting healthy immune responses. Subjects randomized to intervention will take vitamin D supplied as a liquid in a dropper (1 drop per day added to food) for 1 year.
Study NCT01136603 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TIGR Mesh
Description: TIGR mesh as a reconstruction material for the repair of the abdominal wall post Lipectomy, TRAM / DIEP flap.
Study NCT01136603 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TIGR Mesh
Description: TIGR mesh as a reconstruction material for the repair of the abdominal wall post Lipectomy, TRAM / DIEP flap.
Study NCT01682109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Study NCT02188719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Pre-medication for single dose darTreg infusion (Cohorts 2 - 4). 25-50mg of diphenhydramine will be administered intravenously or by mouth 30-60 minutes prior to the darTreg infusion.
Study NCT02188719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Infective Prophylaxis
Description: Intravenous ganciclovir and/or oral Valcyte will be administered for the prophylaxis of cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) for at least six months after liver transplantation.
Study NCT02188719 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Leukapheresis is necessary to ensure collection of adequate numbers of autologous Tregs to support ex vivo expansion of darTregs for infusion after liver transplantation.~Participants enrolled in Cohorts 3 and 4 will undergo leukapheresis. Participants enrolled in Cohort 2 will have either whole blood collection or leukapheresis for the purpose of isolating autologous Tregs for later manufacture. If a cohort 2 subject has a hemoglobin level >/=10.5 gm/dL, he or she will undergo phlebotomy. If the patient has a hemoglobin level \</=10.5 gm/dL and remains eligible for the study, the patient will undergo leukapheresis.
Study NCT02188719 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood draws
Description: Blood draws are necessary to carefully and frequently evaluate allograft function after liver transplantation and treatment with Treg-supportive IS as well as after darTreg infusion. Peripheral blood samples will be collected and analyzed per protocol throughout subject participation in this study.
Study NCT02545439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 5461
Description: Sublingual tablet given alone and in conjunction with Rifampin
Study NCT01622296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium bicarbonate
Description: 8.4% neutralizing solution
Study NCT01622296 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Description: 2% lidocaine with 1:100,000 ppm epinephrine
Study NCT02896257 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Guideline treatment recommendations
Description: Patient-tailored E-consult, orders and rationale to discontinue inhaled corticosteroids and discontinue or receive other COPD related care.
Study NCT02394821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polihexanide 2%
Study NCT02394821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole 0.8%
Study NCT00371371 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow punction
Description: A total volume of 100 ml bone marrow will be aspirated from the iliac crest under local anaesthesia (lidocaine) according to local routine. To maximise the patients comfort, 5-10 mg midazolam and 50 ug fentanyl will be administered intravenously.
Study NCT00371371 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Bone marrow punction
Description: A total volume of 100 ml bone marrow will be aspirated from the iliac crest under local anaesthesia (lidocaine) according to local routine. To maximise the patients comfort, 5-10 mg midazolam and 50 ug fentanyl will be administered intravenously.
Study NCT00371371 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BM-MNC infusion
Description: Repeated intra-arterial infusion of autologous BM-MNC into the common femoral artery
Study NCT00371371 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo infusion
Description: Repeated intra-arterial infusion of placebo (PBS/4% HAS/heparin, coloured with autologous erythrocytes to match the colour of BM-MNC suspension) into the common femoral artery.
Study NCT03454230 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positioning schedule
Description: Applying repositioning schedule daily adapted to pressure ulcer risk assessed with Braden scale. Then, the nurse will applied oil for PU prevention and repositioning which frequency will be defined by the Braden score. The positions will be the semi-fowler 30-30, the half-sitting position with a 45° angle position and patient lying on their back with the head up with a 30° angle for ventilator associated pneumonia prevention.~Repositioning schedule will be applied according to the daily medical prescription. When physician allows to sit the patient on a chair, this have to be done by raising feet on a stool. Therefore, patients will stay in that chair as long as defined by positioning schedule. When patient is returned to bed, same positions as described above will be used alternately. In the time of positioning care, oil usually used for PU prevention will be applied on the skin of the areas of high risk of PU (heels, sacrum, elbows, trochanter, knees) and bone projections.
Study NCT04444089 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: lung ultrasound
Description: Lung ultrasound with a curvilinear probe (DDED) is performed in all patients in a supine position on the lateral wall of the chest at approximately the level of the lower ribs using an ultrasound probe at a frequency of 4-12 MHz (AcusonX300, Siemens Korea, Seoul, South Korea). The mean number of B-lines detected on the ultrasound image and the percentage of patients who showed B-lines on their images were recorded. The mean of three measurements is used. Inter-observer variability is estimated to be 0.766 (95% confidence interval 0.675-0.847).
Study NCT01781884 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gamma Aminobutyric Acid (GABA)
Description: two dosages will be used in this study. GABA: 50mg/kg/day and 100mg/kg/day
Study NCT01781884 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04446403 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suprascapular Nerve Block
Description: The patient will be put in sitting down position with upper limbs pending beside the body then a high-frequency linear ultrasound probe will be positioned transversely above the spine of the scapula. The suprascapular nerve often appears as hypereccoic structure at the suprascapular notch. A 20-gauge spinal needle will be advanced in-plane from medial to lateral 10mL of bupivacaine 0.25% into the suprascapular notch deep to the superior transverse scapular ligament (STSL) and adjacent to the suprascapular artery (SSA) .
Study NCT04446403 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary Nerve Block
Description: Patient will be put in sitting position, with the shoulder in full adduction. linear transducer (8-14 MHz) will be positioned in the short axis orientation at the neck of humerous to identify the axillary artery about 1 to 3 cm from the skin surface.The artery is the most reliable landmark, then a 21-gauge 90 mm needle will be advanced in-plane and 10 mL of bupivacaine 0.25% will be injected adjacent to the artery.
Study NCT04446403 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: posterior cord block
Description: Patient will be put in supine position with head turned away from side that will be blocked with the arm abducted 90 and flexed at the elbow then linear transducer (8-14 MHz) will be positioned in short-axis just medial to coracoid process.Once the artery will be identified, an attempt will be made to identify the hyperechoic cords of the brachial plexus and their corresponding positions relative to the artery, although these may not always be identifiable. The needle will be inserted in plane from the cephalad end of the probe. 10 mL bupivacaine 0.25% will be injected at the posterior cord.
Study NCT04446403 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General anesthesia
Description: General anaesthesia will be induced after giving nerve block in a standardized way with propofol 1.5-2.5mg/kg, fentanyl 2-3 µ/kg and atracurium 0.5mg/kg. maintenance of anaesthesia with isoflurane and atracurium 0.1mg/kg/20min.
Study NCT02112643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium selenate
Description: A 100 microgram pill will be orally administered twice a day for 6 months.
Study NCT02112643 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: The placebo pill will be constructed to look exactly like the selenium pill, but will have no active ingredients. This will be orally administered for 6 months.
Study NCT01979614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serelaxin
Description: Serelaxin solution diluted in 5% glucose volume/volume (v/v) solution
Study NCT01979614 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5% v/v glucose solution
Study NCT00790049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-371797, p38 inhibitor; oral
Description: single dose and multiple dose, escalating
Study NCT00790049 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo; oral
Description: matching placebo
Study NCT00488514 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Combination Tablet of Treximet (sumatriptan/naproxen sodium)
Description: Combination Tablet of Treximet(sumatriptan/naproxen sodium)
Study NCT00730756 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Furoate Nasal Spray
Description: Fluticasone furoate nasal spray 110mcg intranasally once daily for 4 weeks
Study NCT00730756 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nasal Spray
Description: Matching placebo nasal spray intranasally once daily for 4 weeks
Study NCT01641107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Treatment:~Patients will receive daily oral administration of Ponatinib at a dose of 45 mg/day for 6 weeks (defined as one course) for 8 courses, same dose and schedule, for a total of 48 weeks. Each patient will be followed for the subsequent 24 months, every 3 month, providing survival information and monitoring serious adverse event. Each patient should be treated for a minimum of 6 weeks. Patients must be discontinued from the trial in the event of myocardial infarction or stroke, or for development or progression of arterial disease necessitating revascularization. Once a complete hematologic response has been achieved, with a platelet count ≥ 50x109/L, patients can be treated with aspirin and/or a statin as clinically indicated, at investigator discretion.
Study NCT00517699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera/Rituxan]
Description: 750mg/m2 iv
Study NCT00517699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 8g/m2 iv
Study NCT00517699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 2g/m2 iv
Study NCT01102595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: * Temozolomide 85 mg/m2/d x 21 days every 28 days for 2 cycles.~* Temozolomide 75 mg/m2/d x 42-49 days~* Temozolomide 150 - 200 mg/m2 d1-d5 q 28d for 6 cycles.
Study NCT01102595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: * 2 cycles + bevacizumab 10 mg/kg every 15 days each two cycles.~* Bevacizumab 10 mg/kg every 15 days, three dosis.
Study NCT01102595 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Standard radiation therapy
Description: 42-49 days with standard radiation therapy (60 Gy): 2 Gy per day.
Study NCT02629926 — intervention group
Intervention type: OTHER
Intervention: GH Replacement (NutropinAq®)
Description: GH Replacement continued.
Study NCT02629926 — intervention group
Intervention type: OTHER
Intervention: No additional treatment
Description: GH Replacement not continued.
Study NCT03571932 — intervention group
Intervention type: BEHAVIORAL
Intervention: Family planning and immunization service integration
Description: The approach involved integration of immunization and family planning services at health facilities. Vaccinators provided brief FP messages one-on-one to mothers and offered a referral for same-day, co-located FP services at the end of each routine immunization visit. For women coming directly for FP, if women had an infant with them, FP providers asked to see the child's health card, checked the return date for the next vaccination and reminded the mother of the date to return. For women without their child or the child health card with them, FP providers reinforced the importance of vaccination, and encouraged the mothers to bring their child for all their vaccines and complete the immunization schedule in a timely manner. A job aid, referral cards, and IEC materials were introduced to support the integration process.
Study NCT01446874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine solution
Description: Toothbrushing 3 times/day for at least 5 days preoperatively using a 0.12% chlorhexidine solution and for the duration of the hospitalization or 5 days postoperatively.
Study NCT00638729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam
Description: midazolam, 7.5 mg p.o., 60-90 min prior to estimated induction time
Study NCT00638729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clonidine
Description: pre-anesthetic medication with clonidine, 150 µg p.o., 60-90 min prior to estimated induction time
Study NCT00638729 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: inert tablet p.o., 60-90 min prior to estimated induction time
Study NCT04420858 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced (experimental) education
Description: See arm description.
Study NCT04420858 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard (control) education.
Description: See arm description.
Study NCT03186105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ambulatory appendicectomy
Description: The intervention consist of an ambulatory care by appendicectomy of the acute appendicitis. The normal care is an appendicectomy and an hospitalisation during 2 or 3 days .
Study NCT02535897 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Flavoured water
Study NCT02535897 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flavoured water + carbohydrate
Study NCT02535897 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flavoured water + carbohydrate + protein
Study NCT04968392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride
Description: 20 mL of 0.25% levobupivacaine plus 0.5 µg/kg dexmedetomidine
Study NCT04968392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Description: 20 mL of 0.25% levobupivacaine plus 1 mL normal saline
Study NCT04458740 — intervention group
Intervention type: OTHER
Intervention: biographical interviews
Description: A sociologist trained in the sociology of cancer, to enable participants to talk about their experiences and clearly distinguish the experiences of each individual
Study NCT04457986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erector spina plane block (ESP)
Description: Patient will receive ultrasound guided regional anesthesia with bupivacaine and intravenous patient controlled analgesia with tramadol
Study NCT04457986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified thoracolumbar interfacial plane block (MTI)
Description: Patient will receive ultrasound guided regional anesthesia with bupivacaine and intravenous patient controlled analgesia with tramadol
Study NCT04457986 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous patient controlled analgesia (IV-PCA)
Description: Patient will receive intravenous patient controlled analgesia with tramadol
Study NCT00658489 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: One group of residents will receive extensive web-based training in the promotion of oral health. The second group of residents will complete a single training module in the prevention of iron deficiency. The third arm consists of parent-child dyads, who will participate in one well-child care visit.
Study NCT02101398 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eldith DC-stimulator, configuration F7A
Description: tDCS will be delivered during a 20 minutes speech-language therapy session
Study NCT02101398 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eldith DC-stimulator, configuration F7C
Description: tDCS will be delivered during a 20 minutes speech-language therapy session
Study NCT02101398 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eldith DC-stimulator, configuration T5A
Description: tDCS will be delivered during a 20 minutes speech-language therapy session
Study NCT02101398 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eldith DC-stimulator, configuration T5C
Description: tDCS will be delivered during a 20 minutes speech-language therapy session
Study NCT02101398 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: eldith DC-stimulator, configuration Sham
Description: Sham tDCS will be delivered during a 20 minutes speech-language therapy session
Study NCT03853044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide 20mg per day administered orally on Day 1, 4, 8, 11 of each 21-day cycle for 6 cycles
Study NCT03853044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 750 milligrams per square metre (mg/m\^2), administered intravenously (IV) on Day 1 of each 21-day cycle.
Study NCT03853044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 50 mg/m\^2 IV, administered on Day 1 of each 21-day cycle.
Study NCT03853044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine 1.4 mg/m\^2 (maximum 2 mg) IV, administered on Day 1 of each 21-day cycle.
Study NCT03853044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 60mg/m2 , Maximum 100 mg , (or equivalent prednisolone or methylprednisolone), administered orally on Days 1-5 of each 21-day cycle.
Study NCT02907658 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROTECT intervention group
Description: The indicated preventive intervention PROTECT consists of a cognitive-behavioral 4-session brief-protocol (90 minutes). It targets empirically identified risk factors of Internet Use Disorder (IUD), i.e. (1) boredom and motivational problems, (2) procrastination and performance anxiety, (3) social behavior and (4) emotion regulation. It addresses both risk-reduction and strength-promotion by cognitive behavioral (CB) interventions such as (1) psychoeducation, (2) cognitive restructuring (identification and modification of dysfunctional cognition), (3) behavior modification (improving problem solving skills, training of functional behavior and reinforcement) as well as (4) improving emotion regulation (training of sensory, imaginative and mindfulness based techniques).
Study NCT03341637 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetravalent Dengue Vaccine (TDV)
Description: TDV subcutaneous injection
Study NCT03341637 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline (0.9% NaCl) subcutaneous injection